MedTrace Logo

Therapeutic Effect of Vonoprazan Versus Dexlansoprazole in Treatment of Gastroesophageal Reflux Disease

NCT06778395 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2025-02-27

No results posted yet for this study

Summary

Gastroenterologists are often hesitated about whether to use the well known PPI in treatment of GERD or the usage of new H/K ATPase inhibitors so its highly needed to test the benefit of each class in Egyptian population to help doctors in decision making

Conditions

  • Vonoprazan
  • Proton Pump Inhibitor
  • Gastroesophageal Reflux Disease

Interventions

DRUG

Dexlansoprazole 60 mg

once daily for 8 weeks

DRUG

Vonoprazan 20 mg bid

twice daily for 8 weeks

Sponsors & Collaborators

  • Zagazig University

    collaborator OTHER_GOV

  • Ayman Magd Eldin Mohammad Sadek

    lead OTHER_GOV

Principal Investigators

  • Ayman Sadek, MD · Zagazig University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06778395 on ClinicalTrials.gov